Product
DTPa-HBV-IPV/Hib
Aliases
Infanrix hexa
1 clinical trial
1 indication
Indication
DiphtheriaClinical trial
A Phase IV, Single-blind, Randomised, Controlled, Multi-country Study to Evaluate the Immunogenicity and Safety of GSK's Infanrix Hexa (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV Hib), When Administered Intramuscularly According to a 2-, 4- and 12-month Schedule in Healthy Infants and ToddlersStatus: Completed, Estimated PCD: 2022-07-25